Fludrocortisone

Generic Name: Fludrocortisone

Brand Names: Florinef

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₉FO_₅

CAS Number: 127-31-1

Unique Ingredient Identifier: U0476M545B

Background: Fludrocortisone is a synthetic mineralocorticoid used in conjunction with hydrocortisone to replace missing endogenous corticosteroids in patients with adrenal insufficiency. It is functionally similar to aldosterone, the body's primary endogenous mineralocorticoid, and is structurally analogous to cortisol, differing only by a fluorine atom at the 9-positio...

Indication: Fludrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical insufficiency in Addison's disease. It is also indicated for the treatment of salt-losing androgenital syndrome.

Associated Conditions: Otitis Externa, Otitis Media (OM), Primary adrenocortical insufficiency, Secondary adrenocortical insufficiency, Salt-losing Androgenital syndrome

Associated Therapies: -

Clinical Trials

Stress & Social Cognition in BPD (Part 2)

Not Applicable

Recruiting

Conditions: Borderline Personality Disorder

Interventions: Drug: Placebo
Drug: Fludrocortisone
Behavioral: Trier Social Stress Test (TSST)
Behavioral: Placebo Trier Social Stress Test (P-TSST)

First Posted Date: 2022-04-04

Last Posted Date: 2024-08-21

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 240

Registration Number: NCT05310253

Locations: 🇩🇪
Charite University, Berlin, Germany

Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients

Phase 2

Suspended

Conditions: Septic Shock

Interventions: Drug: Placebo
Drug: Fludrocortisone

First Posted Date: 2021-08-12

Last Posted Date: 2023-11-18

Lead Sponsor: Rennes University Hospital

Target Recruit Count: 40

Registration Number: NCT05001854

Locations: 🇫🇷
Rennes University Hospital - Intensive Care unit, Rennes, Bretagne, France

Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS

Phase 2

Completed

Conditions: Critically Ill
Septic Shock

Interventions: Drug: Fludrocortisone Acetate
Other: Standard Therapy

First Posted Date: 2020-07-31

Last Posted Date: 2024-01-18

Lead Sponsor: The George Institute

Target Recruit Count: 155

Registration Number: NCT04494789

Locations: 🇦🇺
Blacktown Hospital, Sydney, New South Wales, Australia
🇦🇺
Austin Hospital, Melbourne, Victoria, Australia
🇦🇺
Royal North Shore Hospital, Sydney, New South Wales, Australia

and more 6 locations

Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension

Phase 4

Recruiting

Conditions: Neurogenic Orthostatic Hypotension

Interventions: Other: Placebo
Drug: Fludrocortisone

First Posted Date: 2019-10-16

Last Posted Date: 2023-10-02

Lead Sponsor: H.A.C. PHARMA

Target Recruit Count: 90

Registration Number: NCT04128137

Locations: 🇫🇷
Hôpital Broca (AP-HP), Paris, France

Androgen Reduction in Congenital Adrenal Hyperplasia

Phase 2

Withdrawn

Conditions: Congenital Adrenal Hyperplasia

Interventions: Drug: Placebo
Drug: Abiraterone acetate
Drug: Hydrocortisone
Drug: Fludrocortisone

First Posted Date: 2018-06-07

Last Posted Date: 2023-02-01

Lead Sponsor: University of Texas Southwestern Medical Center

Registration Number: NCT03548246

Locations: 🇺🇸
Children's Medical Center, Dallas, Texas, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
National Institutes of Health, Bethesda, Maryland, United States

and more 1 locations

Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression

Not Applicable

Completed

Conditions: Major Depression

Interventions: Drug: Placebo
Drug: Fludrocortisone
Drug: D-Cycloserine

First Posted Date: 2017-02-23

Last Posted Date: 2020-06-23

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 232

Registration Number: NCT03062150

Locations: 🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany

The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: Fludrocortisone
Drug: Eplerenone

First Posted Date: 2016-08-18

Last Posted Date: 2021-06-08

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 23

Registration Number: NCT02871648

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock

Phase 3

Withdrawn

Conditions: Septic Shock

Interventions: Drug: Placebo
Drug: Fludrocortisone

First Posted Date: 2014-02-24

Last Posted Date: 2014-02-24

Lead Sponsor: Rennes University Hospital

Registration Number: NCT02069288

Locations: 🇫🇷
Service de Réanimation Chirurgicale - Hôpital de Pontchaillou, Rennes, France

Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment

Phase 2

Completed

Conditions: Autonomic Disturbances in Parkinson's Disease

Interventions: Drug: fludrocortisone
Drug: Pyridostigmine bromide

First Posted Date: 2013-11-25

Last Posted Date: 2021-01-25

Lead Sponsor: Christian Baumann

Target Recruit Count: 18

Registration Number: NCT01993680

Locations: 🇨🇭
University Hospital Zurich, Division of Neurology, Zurich, ZH, Switzerland

Fludrocortisone and Information Processing in Healthy Volunteers

Phase 1

Completed

Conditions: Depression

Interventions: Drug: Placebo
Drug: Fludrocortisone

First Posted Date: 2012-07-25

Last Posted Date: 2014-02-25

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 40

Registration Number: NCT01648998

Locations: 🇳🇱
Leiden University - Institute of Psychology, Leiden, Zuid-Holland, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy